Ongoing Clinical Studies in Bladder Cancer
Cretostimogene grenadenorepvec (CG0070) is currently being evaluated in multiple studies including Phase 1b/2, Phase 2, and Phase 3 studies in the U.S. in BCG unresponsive NMIBC and MIBC. Two studies are actively recruiting. Studies are on-going in South Korea, Japan, China, Taiwan, Australia, and Canada.
Trial Title | Trial Number | Stage | Status | Publication |
---|---|---|---|---|
BOND-002 Safety and Efficacy |
Phase 2, US only |
Completed |
||
BOND-003 Phase 3 |
Phase 3, Global (US, Japan, South Korea, Taiwan, Australia, Canada) |
|||
CORE-001 Phase 2, CG0070 Combined With Pembrolizumab |
Phase 2, Global (US, South Korea) |
Active, Not Recruiting |
||
CORE-002 Phase 1 Study With Nivolumab Ineligible Cisplatin with MIBC |
Phase 1b/2, US Only |
Recruiting |
Patients and Urologists interested in participating should contact:
JoAnn Horn
phone: 516-456-1415
joann.horn@CGOncology.com.
Partners
CG Oncology is eager to partner with companies who share our passion for improving patients and their loved one’s lives. Collaborations could be in R&D, business development or clinical trials. Our partners include:
- Merck
- Bristol Myers Squibb
- Roche
- Kissei Pharmaceutical Co.
- LEPU Medical Holdings
- FUJIFILM Diosynth Biotechnologies
If you are interested in becoming a partner with us, please contact us at bd@cgoncology.com